Novo Nordisk's raised forecast fails to change the debate over its obesity business

Novo Nordisk raised its full year outlook late Tuesday. Analysts said the better-than-expected quarter benefited from rebate adjustments and other temporary factors, while obesity drug sales were largely in line with expectations and oral Wegovy slightly missed forecasts.

Related Symbols 1

N NVO NVO

Source: CNBC

Visit Source

0 0 0

Comment

Important Notice: More than 48 hours have passed since this news or analysis was published. Due to the volatility of financial markets, some of the information or data presented may no longer be valid or reflect current market conditions. Please verify the information again before making any trading or investment decisions.

Comments

No comments yet

Be the first person to comment on this news item.

Category Stock

Source CNBC

Published 1 month ago

Likes 0

Comments 0

Shares 0

News ID #616

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.